Centro Hospitalar Universitario Cova Da Beira E.P.E.
- Address
- lock Available on a paid plan
Cardiovascular Research at Centro Hospitalar Universitario Cova Da Beira
The Immunohemotherapy Department at Centro Hospitalar Universitario Cova Da Beira E.P.E. focuses on cardiovascular diseases, investigating conditions such as acute coronary syndrome, atrial fibrillation, and stroke‑related events. Current trials aim to test new anticoagulant and heart‑failure therapies to improve prevention of clot‑related complications and reduce major cardiovascular outcomes.
- Milvexian versus apixaban for stroke and systemic embolism prevention in atrial fibrillation
- Asundexian safety and efficacy compared with apixaban in high‑risk atrial fibrillation patients
- Finerenone’s impact on heart‑failure events and cardiovascular death in acute decompensated HFmrEF/HFpEF
- Milvexian’s role in lowering major adverse cardiovascular events after myocardial infarction
- Evaluation of milvexian after acute ischemic stroke or high‑risk transient ischemic attack
With five active studies led by three investigators, the site is contributing to the development of safer, more effective treatments for stroke, heart attack, and chronic heart‑failure conditions across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Colorado Prevention Center1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar Universitario Cova Da Beira E.P.E.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Milvexian | 3 | Unknown | 2023-08-04 | 2023-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.